- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01482871
Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
Safety Study of ALG 1001 to Treat Diabetic Macular Edema
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico
- APEC Hospital La Ceguera
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects, 18 years of age or older.
- Patient (male or female) with active diabetic macular edema (DME).
- Patient whose study eye has a best corrected visual acuity (BCVA) of 20/50 to 20/160 ETDRS equivalent (65 letters to 36 letters), that in the opinion of the investigator is primarily due to DME will be intravitreally injected with 0.10 cc containing 1.5mg/100µl or 2.5mg/100µl of ALG-1001. Decrease in BCVA must be assessed based on clinical exploration, macular thickening, presence of clinical significant macular edema and/or OCT findings consistent with diabetic macular edema.
- Patient whose study eye has a best corrected visual acuity (BCVA) of 20/200 or worse ETDRS equivalent (35 letters or less), that in the opinion of the investigator is primarily due to DME will be intravitreally injected with 0.10 cc containing 5.0mg/100µl or 7.5mg/100µl of ALG-1001. Decrease in BCVA must be assessed based on clinical exploration, macular thickening, presence of clinical significant macular edema and/or OCT findings consistent with diabetic macular edema.
- Patients Intra-Ocular Pressure (IOP) is under control, IOP ≤ 25 mm
- Patient is willing and able to return for all study visits.
- Patient is able to meet the extensive post-op evaluation regimen
- Patient can understand and sign Informed Consent form.
Exclusion Criteria:
1. Patients with Media Opacities or abnormalities that would preclude observation of the Retina.
2. Patients with active Proliferative Diabetic Retinopathy (PDR) in the study eye such as NVE, NVD, Vitreous Hemorrhage, or Neovascular Glaucoma.
3. Patients with current or prior Retinal Detachments, Retinal tears, or Tractional Detachments in either eye.
4. Patients with significant epiretinal membranes determined by the investigator to be contributing to the macular edema.
5. Patients with other retinal pathologies that would interfere with their vision.
6. Patient that has Chronic or Recurrent Uveitis. 7. Patient that has undergone Vitrectomy (anterior or pars plana) in the study eye.
8. Patient has ongoing Ocular infection or inflammation in either eye. 9. Patient has a history of intravitreal injections of any type in the study eye within the last 45 days prior to study enrollment.
10. Patient has a history of focal laser of any type in the study eye within the last 90 days prior to study enrollment.
11. Patient has a history of cataract surgery complications/vitreous loss in the study eye.
12. Patient has congenital eye malformations in the study eye. 13. Patient has a history of penetrating Ocular Trauma in the study eye. 14. Patient is mentally handicapped. 15. Patient is Pregnant or Nursing female. If subject is 18 to 60 years old. Negative pregnancy test during the screening window.
16. Patient that is currently participating in any other Clinical Research Study 17. Patient has contraindication to the study medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1.5 mg ALG-1001
Group Using 1.5 mg per 100 ul of ALG-1001
|
1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
|
Experimental: Arm 2.5 mg ALG-1001
Group Using 2.5 mg per 100 ul of ALG-1001
|
1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
|
Experimental: Arm 5.0 mg ALG-1001
Group Using 5.0 mg per 100 ul of ALG-1001
|
1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
|
Experimental: Arm 7.5 mg ALG-1001
Group Using 7.5 mg per 100 ul of ALG-1001
|
1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observation of dose limiting toxicity
Time Frame: 6 months
|
The primary endpoint of this study is observation of dose limiting toxicity and the maximum tolerated dose.
This determination will be made by the following criteria : Ocular Adverse Events by standard Clinical Ophthalmic examination Visual acuity changes from BCVA (ETDRS equivalent) at baseline by Slit Lamp Bio-microscopy, Tonometry, Indirect Ophthalmoscopy/ Fundus Photography, Fluorescein Angiography, OCT Central Macular Thickness, and ERG Examination
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvements in BCVA ETDRS
Time Frame: 6 months
|
Reduction in OCT central macular thickness in subjects with baseline diabetic macular edema and Improvements in BCVA ETDRS letters at 4 meters from baseline to 30 days, 60 days and 90 days post injection evaluations with safety evaluations to 180 days
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hugo Quiroz, M.D, Denver Medical Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Focus 2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on ALG-1001
-
Allegro Ophthalmics, LLCCompletedMacular DegenerationMexico
-
Allegro Ophthalmics, LLCCompletedDry Age-related Macular DegenerationUnited States
-
Allegro Ophthalmics, LLCCompletedSymptomatic Focal Vitreomacular AdhesionUnited States
-
Aligos TherapeuticsTerminatedChronic Hepatitis BKorea, Republic of, China, Hong Kong, United Kingdom, New Zealand, Moldova, Republic of
-
Aligos TherapeuticsTerminatedChronic Hepatitis BNew Zealand, Bulgaria, Moldova, Republic of, Romania
-
Aligos TherapeuticsCompletedNASH - Nonalcoholic SteatohepatitisFrance
-
Aligos TherapeuticsTerminatedChronic Hepatitis BUnited Kingdom, New Zealand
-
University of ChicagoAsphelia PharmaceuticalsCompletedAllergic RhinitisUnited States
-
Mersana TherapeuticsCompletedSmall Cell Lung Cancer | Non-small Cell Lung CancerUnited States
-
K36 Therapeutics, Inc.RecruitingMultiple Myeloma | Myeloma | Myeloma MultipleUnited States, France, Spain, Canada